ClinicalTrials.gg

Program

SAL067

A development code.

Its studies are mostly in Diabetes Mellitus, Type 2, led by Shenzhen Salubris Pharmaceuticals.

Furthest: phase 3, since Mar 9, 20233 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shenzhen Salubris Pharmaceuticals30 open or runningphase 3since Mar 9, 2023Mar 9, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 9, 2023First studies: 2 phase 3 studies in Diabetes Mellitus, Type 2First studyNCT05782192, NCT05801627
  2. Mar 3, 2025Phase 1 study in Diabetes Mellitus, Type 2NCT06883656 · 18 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06883656Diabetes Mellitus, Type 2 · China1CompletedNov 1, 202218
NCT05801627Diabetes Mellitus, Type 2 · China3CompletedMay 24, 2022408
NCT05782192Diabetes Mellitus, Type 2 · China3CompletedMar 25, 2022458

How it is read

Names in the registry

  • “SAL067”, 3 entries

Codes read as this program: SAL067.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
SAL067 (Shenzhen Salubris Pharmaceuticals): development program | ClinicalTrials.gg